We further investigated the association between subclasses and the expression of 15 potentially targetable immune checkpoint genes that were chosen based on current drug inhibitors in clinical trials or have been approved for specific cancer types, and the results indicated that C2 exhibited higher expression for 14 immune checkpoint genes (except for LAG3) than C1 and C3 (Fig. 3C). The gene discussed is LAG3; the disease is cancer.